Capital World Investors Has $298.84 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Capital World Investors decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 49.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,842,620 shares of the medical device company's stock after selling 3,785,016 shares during the quarter. Capital World Investors owned 0.98% of DexCom worth $298,841,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new position in DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA increased its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.88 on Friday, reaching $71.66. 2,857,741 shares of the company's stock were exchanged, compared to its average volume of 4,236,941. The business's 50-day moving average is $73.46 and its two-hundred day moving average is $76.61. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The firm has a market capitalization of $28.10 billion, a price-to-earnings ratio of 50.11, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.